琥珀酸美托洛尔治疗慢性心力衰竭的效果分析(1)
 |
| 第1页 |
参见附件(1683KB，2页)。
[摘要] 目的：研究琥珀酸美托洛尔缓释片对慢性充血性心力衰竭(CHF)患者的心功能改善情况。方法：将60例患者随机分为治疗组(30例)与对照组(30例)，治疗组患者在常规用药的基础上，应用琥珀酸美托洛尔缓释片进行治疗，观察对比两组治疗6个月前后的左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左心室射血分数(LVEF)等心功能指标和愈后情况。结果：两组治疗前比较LVEDD、LVESD、LVEF及B型钠尿肽(BNP)参数值水平比较，差异无统计学意义(P>0.05)；治疗后，两组的LVEDD、LVEF及BNP参数值比较，差异有统计学意义(P<0.05)，证明琥珀酸美托洛尔能改善患者心功能指标。结论：琥珀酸美托洛尔能显著改善慢性充血性心力衰竭患者的心脏功能。
[关键词] 琥珀酸美托洛尔；慢性充血性心力衰竭；效果
[中图分类号] R541.61 [文献标识码] A [文章编号] 1673-7210(2011)11(c)-080-02
Analysis of the effect on Metoprolol Succinate in the treatment of chronic heart failure
SHI Hong
Department of Cardiology, Gulou Hospital Affiliated to Nanjing University, Jiangsu Province, Nanjing 210000, China
[Abstract] Objective: To study the cardiac function improvement of Metoprolol sustained-release tablets in the patients with chronic congestive heart failure (CHF). Methods: 60 patients were randomly divided into treatment group (30 cases) and control group (30 cases). The treatment group was given Metoprolol sustained-release tablets on basis of routine therapy. The left ventricular end diastolic dimension (LVEDD), left ventricular end systolic dimension (LVEF) and other cardiac index and the healing situation were examined before and after 6 months of therapy. Results: The LVEDD, LVESD, LVEF, BNP level parameters of the two groups before treatment had no significant difference (P>0.05); the differences of LVEDD, LVEF and BNP parameters after treatment between the two groups were statistically significant (P<0.05), which showed that Metoprolol Succinate could improve cardiac function in patients. Conclusion: The application of Metoprolol Succinate sustained-release tablets can control the ventricular rate effectively, improve heart function significantly and also reverse left ventricular in patients with chronic atrial fibrillation and chronic heart failure.
[Key words] Metoprolol Succinate; Chronic congestive heart failure; Efficacy
自1957年Waagstein等[1]首次研究发现采用β受体阻滞剂对治疗充血性心力衰竭(congestive heart failure，CHF)有明显的改善效果以来，β受体阻滞剂的疗效越来越受到临床医师认可，并开始应用其治疗CHF，临床上取得了不错的疗效，同时还不同程度地提高了患者的远期生存率和生活质量，降低了死亡率。大量文献表明，β受体阻滞剂可明显改善充血性心力衰竭患者的症状、运动耐量，降低病死率[2]。本研究旨在研究应用β受体阻滞剂琥珀酸美托洛尔改善CHF患者心功能方面的疗效 ......
您现在查看是摘要介绍页，详见PDF附件(1683KB，2页)。